Agyany Pharma LTD’s Post

FORTUNE'S FINESSE In 1928, Alexander Fleming, a Scottish bacteriologist, noticed something unusual in his lab. A Petri dish containing Staphylococcus bacteria had been left open and contaminated with mold. Surprisingly, the bacteria around the mold were dead. Instead of dismissing the contamination as a failure, Fleming’s curiosity drove him to investigate and explore. Fleming had stumbled upon penicillin, the first true antibiotic - a "miracle drug" of the time. Over the next decade, scientists, governments, and pharmaceutical companies collaborated to ensure mass production of penicillin. So important was penicillin during WW2 that scientists worked around the clock to manufacture 2.3 million doses of it in preparation for the D-Day landings!! Fleming’s discovery didn’t just treat infections; it revolutionized healthcare. It paved the way for the development of other antibiotics, drastically reducing deaths from bacterial infections and enabling advances in surgery and other medical fields. It saved countless lives and changed the course of medical history. In life and work, sometimes the impact of our actions and discoveries can far exceed our initial expectations. Also, often the right collaboration has the potential to amplify the impacts of our actions. This is not very different from the markets – an attention to a small detail and that little extra effort can provide insights that help home in on the elusive “winning” stock. And yes, while a lucky “tip” could come your way, actioning it is a different ball game altogether. On that note, relax unwind and yes read the Weekender. Source : Nuvama #FiT365 #FiT365Learnings #FiT365Retreat #FiT365BestSeller

While survival and function are two crucial endpoints for rare diseases such as Amyotrophic lateral sclerosis (ALS), it is equally important for efficient drug development overcoming regulatory challenges. What breakthroughs are on the cusp for rare and orphan diseases that make you hopeful for patients? Join the panel discussion led by Mike Ward, Global Head of Thought Leadership, Life Science & Healthcare at Clarivate, Rob Etherington, CEO at Clene Nanomedicine, Inc. and Neil McFarlane, CEO at Zevra Therapeutics to examine the dynamic role data might play in rare disease and personalized medicine. View the on-demand webinar to determine what companies need to be doing to address this complex and evolving field, here: https://lnkd.in/eHsQxAMw #raredisease #regulatory #IRA #ALS

𝐁𝐢𝐨𝐡𝐨𝐩𝐞 𝐒𝐞𝐜𝐮𝐫𝐞𝐬 €𝟐𝐌 𝐆𝐫𝐚𝐧𝐭 𝐟𝐨𝐫 𝐌𝐓𝐗-𝐂𝐄𝐋𝐋 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭   ⚫ Spanish biotech company Biohope has received a €2 million grant from the Comunidad de Madrid to advance its diagnostic device, MTX-CELL, which predicts Methotrexate (MTX) efficacy in Rheumatoid Arthritis (RA) patients. This groundbreaking tool enables personalized treatments, improving outcomes and reducing healthcare costs.   ⚪ The grant, part of the Seal of Excellence initiative by the 𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐂𝐨𝐮𝐧𝐜𝐢𝐥 (𝐄𝐈𝐂) 𝐀𝐜𝐜𝐞𝐥𝐞𝐫𝐚𝐭𝐨𝐫, recognizes high-quality projects. ARISTOS Innovation Funding by PNO Innovation (Spain) played a key role in helping Biohope achieve this prestigious recognition! 🔵 With this funding, #Biohope will finalize and validate MTX-CELL, bringing it closer to clinical practice and benefiting patients, providers, and healthcare systems alike. 𝐌𝐨𝐫𝐞 𝐢𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 👉🏾 https://lnkd.in/dgCFB2Wy #Aristos #PNOSpain #PNOGroup #EICAccelerator

🌟 #BioEurope is just around the corner, and we invite #pharma partners to connect with us and explore our cutting-edge product pipeline! 👉 Join us at booth #150 to explore Scinai Immunotherapeutics Ltd. #VHH #sdAb pipeline of Alpaca-derived nanobodies exclusively licensed from Max Planck Institute and the University Medical Center Göttingen. 📍Our pipeline targets diseases with significant unmet needs, including #psoriasis and #asthma, with a focus on underserved patient populations. 🎯 Our nanobodies offer unique properties, enabling targeted biologic delivery and expanding access to those previously limited by cost or side effects. 📍 With pre-clinical proof-of-concept studies completed and a psoriasis program entering clinical trials in 2025, we’re seeking partners to help bring these innovations forward. 🤝Let’s connect at #BioEurope to explore collaboration opportunities. Scinai offers advanced labs and #cGMP manufacturing capabilities in Israel, making us a strong and self-sufficient partner. 👉👉 Schedule a meeting via the BioEurope Partnering One platform or drop us an email at bd@scinai.com We look forward to meeting you at #BioEurope24 Amir Reichman Dalit Fischer

As we continue to forge ahead with our new partnership with AstralBio, the enthusiasm within and around our teams is palpable. Following our initial announcement, it's time to spotlight the remarkable expertise that Martin Brenner, iBio's CEO and CSO, brings to this venture, especially in cardiometabolic disease research. With a career that spans industry giants like Eli Lilly and Pfizer, Martin's contributions to obesity and cardiometabolic disease drug development have been nothing short of revolutionary. His words resonate with our mission: "Leveraging my experience in obesity and cardiometabolic disease drug development from my time at Eli Lilly and Pfizer, I am eager to advance potentially groundbreaking compounds through our partnership with AstralBio." Martin's expertise is a testament to iBio's strategic approach, which is focused on tackling some of the most challenging healthcare issues facing the world today. His vision and deep understanding of the intricacies of developing therapies for obesity and cardiometabolic diseases are invaluable as we collaborate with AstralBio. Together, we aim to create therapies and revolutionize how these conditions are treated globally. This partnership is a testament to our unwavering commitment to leveraging unparalleled expertise and innovative technologies to develop therapies that can profoundly impact patients' lives. With Martin Brenner leading iBio's scientific endeavors, we are more confident than ever in achieving extraordinary outcomes that will make a real difference to patients worldwide. #iBio #AstralBio #Biotech #Collaboration #CardiometabolicHealth #DrugDevelopment

We were proud to be selected as one of the Fierce Biotech Fierce 15 2024 Honorees. We asked ourselves – what makes us fierce? Here is what our team said #4. Patients are our purpose: We act with a sense of urgency to our work and commitment to colleagues and patients. We are tackling some of the hardest targets to drug, to develop life-changing medicines for rare and under treated orphan and immunological diseases. It’s our purpose to improve people’s lives. Read more about how OMassians are transforming lives together, our values and our team HERE: https://lnkd.in/ddaju6xf #innovation #biotech #drugdiscovery

🔬Are we ready to move beyond our traditional reliance on animal models and fast-track treatment breakthroughs in liver disease? Quin Wills, our CSO and co-founder, recently wrote in PharmaTimes Media Ltd about the need for improved liver therapies in light of the escalating mortality rates associated with chronic liver diseases. He described his belief that technology and human data will play a transformative role in accelerating research, evidenced by our "human first" approach to therapy development and validation, and how we are utilising deep genomic phenotyping and computational biology for comprehensive liver analysis. Our "fully human, super speedy liver drug development" was also profiled in an emerging company profile by BioCentury Inc. Read the articles ⬇️ 1️⃣ PharmaTimes Media Ltd (page 32): https://lnkd.in/epAr-kKp 2️⃣ BioCentury Inc. (paywall): https://lnkd.in/eME-Yp4j #TeamOchre #biotech #genomics #LiverDisease

BREAKING NEWS AT #ACR24: #LupusTherapeutics, the clinical affiliate of #Lupus Research Alliance, is encouraged by the positive Phase 3 PHOENYCS GO data reported by UCB and Biogen during #ACR24. Study sponsors provided a detailed analysis of the pivotal trial to evaluate the efficacy and safety of dapirolizumab pegol (DZP) in patients with moderate-to-severe systemic #lupus erythematosus (SLE). As a proud partner in this study, #LupusTherapeutics contributed clinical expertise and leveraged LuCIN site support to advance #lupusclinicalresearch. Read more: https://lnkd.in/gEP3XgXK

🚀 Breaking News in Biotech! 🚀 Critical Path Institute (C-Path) and CENTOGENE have signed an MoU to enhance collaboration in lysosomal disease research and drug development! 🧬💊 Key Highlights: -New Partnership: C-Path and Centogene join forces. -Focus Area: Advancing lysosomal disease research. -Objective: Accelerate the development of new treatments. Why It Matters: -Enhanced Research: Leveraging combined expertise to deepen our understanding of lysosomal diseases. -Innovative Solutions: Driving forward the development of groundbreaking therapies. -Global Impact: Aiming to improve health outcomes for patients worldwide. #Biotech #HealthcareInnovation #LysosomalDisease #DrugDevelopment #MedicalResearch #CPath #Centogene #RareDiseases #PharmaPartnerships #ScientificBreakthroughs

📘 New publication! CARB-X product developer Trellis Bioscience Inc. completed a first-in-human phase 1 clinical study that supports the further development of TRL1068 for the treatment of biofilm-associated infections, including medical device-associated infections and bacteremia. TRL1068 is a native human monoclonal antibody that disrupts bacterial biofilms with broad-spectrum activity against both Gram-positive and Gram-negative species. Evidence of efficacy, safety and pharmacokinetic data from this phase 1 study will help guide future phase 2 and 3 studies of TRL1068. 🔗 Read here: bit.ly/3LM3Avb #AMR #StopSuperBugs #SuperBugs #AntibioticResistance #Medicine #GlobalHealth #ProductDevelopment #Innovation #Biotechnology